Top

Published in:

01-08-2015 | Original Article

Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy

Authors: Alexandra Masson-Lecomte, Evanguelos Xylinas, Morgane Bouquot, Mathilde Sibony, Yves Allory, Eva Comperat, Marc Zerbib, Alexandre de la Taille, Morgan Rouprêt

Published in: World Journal of Urology | Issue 8/2015

Abstract

Objective

To assess the oncological outcomes of radical cystectomy (RC) and adjuvant chemotherapy to treat muscle-invasive bladder cancer (MIBC) with a micropapillary component (MPC), and to compare outcomes with those from pure urothelial carcinoma (PUC).

Materials and methods

A retrospective review of clinicopathological and follow-up data was performed for all patients treated by RC and adjuvant platinum-based chemotherapy for advanced MIBC in three tertiary reference centers between 1999 and 2012. Uni- and multivariate Cox’s regression analyses evaluated the association of the presence of MPC with disease recurrence and cancer-specific mortality.

Results

Two hundred and thirty-five (88 %) PUC and 31 (12 %) MPC cases were included. Median age was 65 (39–83) years in the PUC group and 62 (45–80) years in the MPC group. Median survival was 29 months in the MPC versus 31 months in the PUC group. No significant difference was observed between the groups regarding main clinical and pathological characteristics. The median number of treatment cycles administered was 6 (3–8) in the PUC versus 5 (3–8) in the MPC group (p = 0.45). Five-year disease-free recurrence and cancer-specific survival (CSS) rates were 15 and 24 %, respectively, in the MPC versus 42 and 47 %, respectively, in the PUC group (p = 0.007 and 0.058). In multivariate analyses, ASA score, soft tissue surgical margins, and MPC were associated with disease recurrence (p = 0.022, 0.001, and 0.015, respectively). We found no association between MPC and cancer-specific mortality (univariate, p = 0.06).

Conclusion

MPC was associated with higher recurrence rates after RC and platinum-based adjuvant chemotherapy than that with pure urothelial tumors.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2012) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11

Howlader NNA, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W et al (2009) SEER cancer statistics review, 1975–2009 (vintage 2009 populations). National Cancer Institute, Bethesda

Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA et al (2012) ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63:45–57PubMedCrossRef

Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF et al (2013) ICUD-EAU international consultation on bladder cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 63:58–66PubMedCrossRef

Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24:3967–3972PubMedCrossRef

Shariat SF, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y et al (2012) Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 187:457–462PubMedCrossRef

Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG et al (2006) Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 12:6663–6676PubMedCrossRef

Xylinas E, Cha EK, Sun M, Rnk M, Trinh QD, Novara G et al (2012) Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer 107:1826–1832PubMedCentralPubMedCrossRef

(2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol, 48: 189–201

10.

Amin MB, Ro JY, El-Sharkawy T, Lee KM, Troncosco P, Silva EG et al (1994) Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 18:1224–1232PubMedCrossRef

11.

Vourganti S, Harbin A, Singer EA, Schuch B, Metwalli AR, Agarwal PK (2013) Low grade micropapillary urothelial carcinoma, does it exist?—analysis of management and outcomes from the surveillance, epidemiology and end results (SEER) database. J Cancer 4:336–342PubMedCentralPubMedCrossRef

12.

Alvarado-Cabrero I, Sierra-Santiesteban FI, Mantilla-Morales A, Hernandez-Hernandez DM (2005) Micropapillary carcinoma of the urothelial tract. A clinicopathologic study of 38 cases. Ann Diagn Pathol 9:1–5PubMedCrossRef

13.

Maranchie JK, Bouyounes BT, Zhang PL, O’Donnell MA, Summerhayes IC, DeWolf WC et al (2000) Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J Urol 163:748–751PubMedCrossRef

14.

Oh YL, Kim KR (2000) Micropapillary variant of transitional cell carcinoma of the ureter. Pathol Int 50:52–56PubMedCrossRef

15.

Samaratunga H, Khoo K (2004) Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology 45:55–64PubMedCrossRef

16.

Vang R, Abrams J (2000) A micropapillary variant of transitional cell carcinoma arising in the ureter. Arch Pathol Lab Med 124:1347–1348PubMed

17.

Fairey AS, Daneshmand S, Wang L, Schuckman A, Lieskovsky G, Djaladat H et al (2013) Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol Oncol 32:110–116PubMedCrossRef

18.

Wang JK, Boorjian SA, Cheville JC, Kim SP, Tarell RF, Thapa P et al (2012) Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World J Urol 30:801–806PubMedCrossRef

19.

Xylinas E, Rink M, Robinson BD, Lotany Y, Babjuk M, Brisuda A et al (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 49:1889–1897PubMedCrossRef

20.

Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P et al (2007) Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110:62–67PubMedCrossRef

21.

Heudel P, El Karak F, Ismaili N, Droz JP, Flechon A (2009) Micropapillary bladder cancer: a review of leon berard cancer center experience. BMC Urol 9:5PubMedCentralPubMedCrossRef

22.

Lopez-Beltran A, Montironi R, Blanca A, Cheng L (2010) Invasive micropapillary urothelial carcinoma of the bladder. Hum Pathol 41:1159–1164PubMedCrossRef

23.

Masson-Lecomte A, Colin P, Bozzini G, Nison L, de La Taille A, Comperat E et al (2014) Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 32:531–537PubMedCrossRef

24.

Alvarado-Cabrero I, Alderete-Vazquez G, Quintal-Ramirez M, Patino M, Ruiz E (2009) Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Ann Diagn Pathol 13:151–157PubMedCrossRef

25.

Warth A, Muley T, Meister M, Stenzinger A, Thomas A, Schirmacher P et al (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446PubMedCrossRef

26.

Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH et al (2013) Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int 111:E325–E330PubMedCrossRef

27.

Siefker-Radtke AO, Dinney CP, Shen Y, Dl Williams, Kamat AM, Grossaman HB et al (2013) A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 119:540–547PubMedCrossRef

28.

Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J et al (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751–757PubMedCrossRef

29.

Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M et al (2013) Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int 111:E30–E36PubMedCrossRef

30.

Sangoi AR, Beck AH, Amin MB, Cheng L, Epstein JI, Hansel DE et al (2010) Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol 34:1367–1376PubMedCrossRef

31.

Thunnissen E, Beasley MB, Borczuk AC, Brambilla E, Chire et al (2012) Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 25:1574–1583PubMedCrossRef

32.

Shah RB, Montgomery JS, Montie JE, Kunju LP (2013) Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol 3:2650–2655

33.

Comperat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaid I et al (2010) Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology 42:650–654PubMedCrossRef

34.

Gaya JM, Palou J, Algaba F, Arce J, Rodriguez-Fabaa O, Villavicencio H (2010) The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol 17:5370–5376PubMed

Title: Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy
Authors: Alexandra Masson-Lecomte
Evanguelos Xylinas
Morgane Bouquot
Mathilde Sibony
Yves Allory
Eva Comperat
Marc Zerbib
Alexandre de la Taille
Morgan Rouprêt
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1387-1

At a glance: The STEP trials

Springer Medicine

Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy

Abstract

Objective

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2015

Complications in percutaneous nephrolithotomy

Utility of urodynamics in the management of asymptomatic tethered cord in children

Temporal expression of hyaluronic acid and hyaluronic acid receptors in a porcine small intestinal submucosa-augmented rat bladder regeneration model

Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer

Nutritional predictors of complications following radical cystectomy

Pelvic floor muscle function is an independent predictor of outcome after retrourethral transobturator male sling procedure